Usefulness of Early Treatment with Efgartigimod in Patients with Generalized Myasthenia Gravis Complicated by Cardiovascular Disease: A Case Report - PubMed
5 hours ago
- #Myasthenia Gravis
- #Efgartigimod
- #Cardiovascular Disease
- Generalized myasthenia gravis (gMG) is an autoimmune disease affecting neuromuscular junctions.
- Conventional fast-acting treatments (FT) like steroid pulses, IVIg, or plasmapheresis may pose risks for gMG patients with cardiovascular diseases.
- A case report highlights successful treatment of gMG with cardiovascular complications using efgartigimod, a neonatal Fc receptor inhibitor.
- Efgartigimod presents a feasible alternative to conventional FT, especially for patients with significant cardiovascular comorbidities.